Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Hutchmed China Ltd (13 HK)
Watchlist
177
Analysis
Industrials
•
Hong Kong
HUTCHMED (China) Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Hutchmed China Ltd
•
10 Nov 2023 19:31
•
Broker
Hutchmed (13 HK) – Big Milestone Achieved with Fruquintinib Successfully Approved by US FDA
The approval was based on the Ph3 MRCT FRESCO-2 (18% patients enrolled from the US) as well as the China FRESCO trial, implying the recognition of...
CMB International
Follow
379 Views
Share
bullish
•
Hutchmed China Ltd
•
03 Aug 2023 08:12
•
Broker
Hutchmed (13 HK) – Eyes on the FDA Approval of Fruquintinib in Nov
HCM’s consolidated revenues from oncology/immunology increased 294% YoY to US$359mn in 1H23, mainly driven by the US$259mn income recognition
CMB International
Follow
214 Views
Share
bullish
•
Hutchmed China Ltd
•
03 Mar 2023 07:53
•
Broker
Hutchmed (13 HK) – Exploit global market opportunities
HCM continued to prove its strong commercial capabilities by achieving remarkable 63% YoY growth in oncology product sales in FY22, reaching...
CMB International
Follow
163 Views
Share
bullish
•
Hutchmed China Ltd
•
15 Sep 2022 09:23
•
Broker
Hutchmed (13 HK) – Fruquintinib to unlock the global potential in mCRC indication
The median line of prior treatments was five, and 91% and 48% of patients had previously received TAS-102 and regorafenib, respectively.
CMB International
Follow
159 Views
Share
1
2
3
4
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x